Surgery Trials

 

ClinicalTrials.gov Identifier:

NCT02617186

This study is currently recruiting participants
 

Robotic lobectomy has been shown, on the basis of non-randomized studies, to have superior outcomes to thoracotomy and Thoracoscopic lobectomy. Despite the potential benefits of robotic technology, there are two major barriers against its widespread adoption in thoracic surgery. The first barrier is the lack of high-quality prospective data. To our knowledge, there are no prospective trials comparing Thoracoscopic Lobectomy to Robotic Lobectomy for early stage lung cancer. The second major barrier to the widespread adoption of robotic technology in thoracic surgery is the perceived higher cost of Robotic lobectomy. To address these barriers, the investigators will undertake the first randomized controlled trial comparing Thoracoscopic Lobectomy to Robotic Lobectomy for early stage lung cancer.
 

Prospective randomization will eliminate the biases of retrospective data and will serve to determine whether there exist any advantages to HRQOL or patient outcomes in favour of Robotic Lobectomy over Thoracoscopic Lobectomy. Furthermore, through a prospective cost-utility analysis, this trial will provide the highest quality data to evaluate the true economic impact of robotic technology in thoracic surgery.

 

St Joseph’s Healthcare, Hamilton

Toronto General Hospital, Toronto 
 

ClinicalTrials.gov Identifier:

NCT04459065

This study is currently recruiting participants
 

The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery
 
Saskatchewan
St. Paul’s Hospital, Saskatoon
 

ClinicalTrials.gov Identifier:

NCT02570815

This study is currently recruiting participants
 

Near-Infrared Fluorescence (NIF) using indocyanine green (ICG) fluorescent dye is a recent advancement in the robotic platform of robotic surgery. The surgeon will view the CT scan to determine which segment the tumour is located in. Once identified, the surgeon will isolate the segment by cutting off the blood supply to that segment. Then ICG will be injected into a vein. It is expected that the entire lung, except the isolated segment, which will remain 'dark' as it was isolated from blood supply, will fluoresce, giving off a green hue when viewed with the da Vinci Firefly camera. The surgeon will identify 'dark' segment, and will remove it. A pathologist will examine the excised tissue to ensure that the tumour was removed in its entirety. Once confirmed, the surgeon will end the procedure. If the pathologist determines that the segment removed did not contain the entire tumour, then the surgeon will perform a routine lobectomy. This ensures patient safety and confirms that all participants will have the entire tumour removed from their lung
 
Ontario
St. Joseph’s Healthcare, Hamilton
Toronto General Hospital, Toronto
 

ClinicalTrials.gov Identifier:

NCT01440244

This study is currently recruiting participants
 

Although thoracic NOTES may not be ready for human trials, a new minimally invasive technique to access the pleural cavity and perform pleural, pulmonary and mediastinal procedures would be possible. Cervical Video Assisted Thoracoscopic Surgery (C-VATS) is a technique that borrows from traditional VATS procedures, from cervical mediastinoscopy, and from flexible endoscopy. All of these procedures are very familiar to the thoracic surgeon.
 

The current feasibility and safety study examines C-VATS as a method of evaluating, biopsying and performing pleurodesis in patients with pleural disease and or effusion.
 

Centre Hospitalier de l'Université de Montréal

Montréal,  H2L 4M1

 

ClinicalTrials.gov Identifier:

NCT05299606

This study is currently recruiting participants